Related Experiment Video

Updated: May 28, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation

Yisheng Jiao1, Wenbin Ou, Fanguo Meng

  • 1Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, P. R. China. yishengjiao@yahoo.com.cn

Molecular Cancer
|October 4, 2011
PubMed
Abstract

Insights

Targeting multiple receptor tyrosine kinases (RTKs) simultaneously shows promise for ovarian cancer treatment. Coordinated inhibition of these RTKs significantly impacts cancer cell proliferation and survival, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Ovarian cancer has a high mortality rate among gynecologic malignancies.
  • Receptor tyrosine kinases (RTKs) are implicated in ovarian cancer, but individual inhibitors show limited benefit.
  • The role of coordinated RTK networks in ovarian cancer tumorigenesis is not well understood.

Purpose of the Study:

  • To investigate the hypothesis that a coordinated network of multi-RTK activation is crucial for ovarian cancer development.
  • To evaluate the efficacy of targeting multiple RTKs compared to individual kinases.

Main Methods:

  • Co-activation of multiple RTKs (EGFR, ERBB2, ERBB4, MET, AXL) was assessed in ovarian cancer cell lines and primary tumors.
  • The effects of coordinate multi-RTK inhibition versus single-kinase inhibition on cancer cell proliferation and survival were compared.
  • The impact of HSP90 suppression on multi-RTK signaling and downstream pathways (PI3-K/AKT/mTOR, RAF/MAPK) was analyzed.

Main Results:

  • Co-activation of multiple RTKs was observed in individual ovarian cancer samples.
  • Coordinate inhibition of multi-RTK signaling demonstrated a significantly greater impact on ovarian cancer proliferation and survival than inhibiting individual kinases.
  • HSP90 suppression led to profound pro-apoptotic and anti-proliferative effects, linked to inactivation of downstream RTK signaling.

Conclusions:

  • Ovarian cancer pathogenesis involves the coordinated activity of multiple RTKs.
  • Targeting multiple RTKs concurrently represents a promising therapeutic strategy for ovarian cancer.
  • This multi-RTK inhibition approach warrants further investigation for clinical application in ovarian cancer treatment.

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...